Open AccessSafety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients
Author(s) -
Daniel Podzamczer,
Montserrat Olmo,
José Sanz,
Vicente Boix,
Eugènia Negredo,
Hernando Knobel,
Peré Domingo,
Juan A. Pineda,
Consuelo Viladés,
José Hernández Quero,
Lluís Force,
J. González Lahoz,
Pepa Muñoz,
Josep M Llibre,
Ana Mariño,
Enrique Ortega,
David Dalmau,
Josep M. Gatell,
Esperanza Antón,
Julio Sola,
Marı́a José Galindo,
Enric Pedrol,
Jesús Sanz,
Javier Torre de Lima,
Juan Flores
Publication year - 2009
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e318198a0cc
Subject(s) - medicine , nevirapine , regimen , confidence interval , alanine transaminase , clinical endpoint , gastroenterology , randomized controlled trial , adverse effect , aspartate transaminase , intention to treat analysis , transaminase , surgery , viral load , human immunodeficiency virus (hiv) , immunology , antiretroviral therapy , biochemistry , alkaline phosphatase , enzyme , chemistry
The strategy of switching nevirapine (NVP) twice daily to once daily was evaluated.